Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2019 | Tailoring CLL therapy

Danielle Brander • 2 Jun 2019
ASCO 2019
Chronic Lymphocytic Leukemia Leukemia

Danielle Brander, MD, of the Duke University School of Medicine, Durham, NC, discusses how clinicians can tailor chronic lymphocytic leukemia (CLL) therapy. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

More from Danielle Brander

1:49
The management of Richter's transformation: current approaches and future outlooks
Danielle Brander • 8 Dec 2023
1:13
Exciting updates in CLL: advancing treatment for patients with double-refractory disease
Danielle Brander • 8 Dec 2023
1:46
Managing the side effects associated with BTKi treatment for CLL
Danielle Brander • 8 Dec 2023
2:06
Unmet need: CLL patients intolerant to novel therapies
Danielle Brander • 22 Sep 2019

Related Videos

1:08
The real-world safety and efficacy of CPX-351 in patients with AML
Priyanka Mehta • 22 Apr 2024
1:17
An ongoing Phase I/II study of sonrotoclax + zanubrutinib in patients with treatment-naive CLL/SLL
Piers Patten • 28 Apr 2024
1:51
Should MRD eradication be the goal when treating every patient with CLL?
Dima El-Sharkawi • 28 Apr 2024
1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
The content of VJHemOnc is intended for healthcare professionals